John C. Pottage

John brings over 20 years of executive and clinical development experience, with an expertise in infectious diseases. He most recently served as Chief Medical Advisor of Clear Creek Bio, Inc. a clinical-stage biotechnology company developing small molecule antiviral therapeutics and prior to that served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare, a joint venture of GlaxoSmithKline and Pfizer focused on treatments for HIV. Prior to ViiV, John served as Senior Vice President, Head of Infectious Disease Medicine Development Center, and Vice President, Global Clinical Development of Antivirals, at GlaxoSmithKline, plc. Prior to joining GlaxoSmithKline, he served as Chief Medical Officer and Senior Vice President of Drug Development of Achillion Pharmaceuticals, Inc. Prior to joining industry, Dr Pottage was a member of the faculty and clinical staff at Rush University Medical College in the Department of Internal Medicine and the Section of Infectious Disease. He currently serves on the board of directors of Spero Therapeutics, Inc.

John is board certified in both Internal Medicine and Infectious Disease by the American Board of Internal Medicine. Dr. Pottage holds an A.B. in Biology from Colgate University and a M.D. from Saint Louis University School of Medicine.